Poxel Past Earnings Performance
Past criteria checks 0/6
Poxel's earnings have been declining at an average annual rate of -17.8%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been declining at an average rate of 18.7% per year.
Key information
-17.8%
Earnings growth rate
-12.5%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | -18.7% |
| Return on equity | n/a |
| Net Margin | -14,151.9% |
| Next Earnings Update | 22 Mar 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Poxel makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 0 | -29 | 9 | 18 |
| 31 Mar 22 | 7 | -26 | 10 | 22 |
| 31 Dec 21 | 13 | -24 | 11 | 25 |
| 30 Sep 21 | 14 | -26 | 10 | 27 |
| 30 Jun 21 | 14 | -28 | 9 | 29 |
| 31 Mar 21 | 10 | -30 | 10 | 28 |
| 31 Dec 20 | 7 | -32 | 10 | 27 |
| 30 Sep 20 | 10 | -30 | 11 | 28 |
| 30 Jun 20 | 14 | -28 | 12 | 29 |
| 31 Mar 20 | 20 | -27 | 12 | 34 |
| 31 Dec 19 | 27 | -26 | 11 | 40 |
| 30 Sep 19 | 35 | -21 | 10 | 46 |
| 30 Jun 19 | 44 | -16 | 9 | 51 |
| 31 Mar 19 | 53 | -7 | 8 | 53 |
| 31 Dec 18 | 62 | 1 | 8 | 55 |
| 30 Sep 18 | 53 | -2 | 7 | 48 |
| 30 Jun 18 | 43 | -5 | 7 | 42 |
| 31 Mar 18 | 24 | -14 | 6 | 32 |
| 31 Dec 17 | 5 | -22 | 6 | 21 |
| 30 Sep 17 | 3 | -22 | 6 | 18 |
| 30 Jun 17 | 0 | -22 | 5 | 16 |
| 31 Mar 17 | 0 | -23 | 6 | 16 |
| 31 Dec 16 | 0 | -24 | 6 | 18 |
| 30 Sep 16 | 0 | -22 | 6 | 15 |
| 30 Jun 16 | 0 | -19 | 6 | 13 |
| 31 Mar 16 | 0 | -16 | 5 | 10 |
Quality Earnings: POXELp is currently unprofitable.
Growing Profit Margin: POXELp is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: POXELp is unprofitable, and losses have increased over the past 5 years at a rate of 17.8% per year.
Accelerating Growth: Unable to compare POXELp's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: POXELp is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: POXELp's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.